MIM
NVCT icon

MetLife Investment Management’s Nuvectis Pharma NVCT Stock Holding History

MetLife Investment Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,970
Closed -$63.4K – 2952
2023
Q2 		$63.4K Buy
+3,970
New +$63.4K ﹤0.01% 2874

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

MetLife Investment Management's NVCT Position: Q3 2023 in Review

MetLife Investment Management sold out of Nuvectis Pharma (NVCT) in Q3 2023, closing a stake of 3,970 shares — an estimated $63.4K sold.

MetLife Investment Management first reported a position in NVCT in Q2 2023 and held it in 1 quarter. The position peaked at $63.4K in Q2 2023. 33 funds tracked by Wall St. Rank hold NVCT as of Q3 2023.

  • MetLife Investment Management reported no remaining Nuvectis Pharma position as of Q3 2023 after selling out during the quarter.
  • MetLife Investment Management sold 3,970 Nuvectis Pharma shares in Q3 2023, an estimated $63.4K.
  • MetLife Investment Management first reported a position in Nuvectis Pharma in Q2 2023 and held it in 1 quarter.
  • MetLife Investment Management's Nuvectis Pharma position peaked at $63.4K in Q2 2023.
  • 33 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.